Leonhardt Ventures Introduces E-Stent™ Bioelectric Platform with 29 Exclusive Medical Applications
TL;DR
Leonhardt Ventures' E-Stent technology offers exclusive licensing opportunities across 29 medical applications, creating first-mover advantages in regenerative medicine markets.
The E-Stent system uses wireless wearable harnesses to deliver bioelectric signals through micro-coils embedded in stents, controlling specific protein expressions for targeted regeneration.
This wireless bioelectric stent platform could significantly improve treatment outcomes for conditions ranging from Alzheimer's to heart disease, potentially enhancing millions of lives worldwide.
Leonhardt Ventures' wireless E-Stent can stimulate proteins like klotho and sirtuins to regenerate organs from brain to pancreas using bioelectric signals.
Found this article helpful?
Share it with your network and spread the knowledge!
Leonhardt Ventures LLC announced the introduction of E-Stent™, the first wireless bioelectric protein-expression stent designed to activate or inhibit specific regenerative proteins directly from vessel walls and surrounding tissues. The technology platform combines a next-generation implant with a wireless wearable harness that delivers controlled protein expressions to micro-coils embedded along the stent, with sizes ranging from micro-implants smaller than a pea to 28 mm aortic stents.
The company has granted exclusive licenses for the E-Stent™ platform across 29 specialized medical applications. KidneyCell™ will focus on kidney regeneration, while CerebraCell™ addresses brain health, stroke recovery, and traumatic brain injury treatment. For neurological conditions, MemoryStim™ targets memory improvement, dementia, and Alzheimer's treatment, and DepressiStim™ focuses on severe depression and anxiety treatment.
Cardiovascular applications include BioLeonhardt™ for heart regeneration and AortaCell™ for aortic aneurysm treatment. The platform extends to oncology with CancerCell™ for cancer treatment, while sensory regeneration is covered by Ear-Cell™ for hearing and Eye-Cell™ for vision restoration.
Other licensed applications include Lionheart Health for healthspan longevity and medical aesthetics, Vascustim™ for peripheral artery disease and wound healing, and SpineStim™ for spinal cord injury recovery. The technology also addresses metabolic disorders through PancreaCell™ for diabetes treatment and pancreas regeneration.
Through selective bioelectric signaling, the E-Stent™ platform can stimulate or inhibit a broad range of proteins including klotho, sestrins, sirtuins, apelin, and many others known to influence regenerative processes. These stimulations can direct stem cell homing, proliferation, and differentiation on demand, improving circulation, restoring muscle strength, modulating inflammation and blood pressure, improving nerve connections, and restoring elasticity.
The platform represents a significant evolution of Leonhardt Ventures' previously announced KlothoImplant Bioelectric MicroImplant, expanding the same core capabilities into advanced vascular implant formats. The development team, led by CTO Brian Lasater and CEO Howard Leonhardt, confirmed that working prototypes are currently in testing and can control regenerative and healing protein expressions on demand enabled fully by wireless energy.
The technology's potential impact spans multiple medical specialties, offering a novel approach to conditions that currently have limited treatment options. By enabling controlled protein expression directly at the tissue level, the E-Stent™ platform could transform treatment paradigms for degenerative diseases, organ failure, and age-related conditions. The broad licensing across 29 applications indicates the platform's versatility and potential to address multiple unmet medical needs simultaneously.
Curated from Newsworthy.ai
